EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

TDP-43 Proteinopathy Specific Biomarker Development

Isabell Cordts, Annika Wachinger, Carlo Scialo, Paul Lingor iD, Magdalini Polymenidou iD, Emanuele Buratti iD, Emily Feneberg

Cells · 12.02.2023 · 12 (4) · 597

DOI: 10.3390/cells12040597 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 12.02.2023. Verfasst von Isabell Cordts und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Klinikum Rechts der Isar, School of Medicine, Technical University of Munich, 81675 Munich, Germany. Hauptthemen laut MEDLINE: TDP-43 Proteinopathies, Amyotrophic Lateral Sclerosis, Frontotemporal Dementia. Die Arbeit wurde bisher 47-mal zitiert (Crossref) und nennt 206 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

TDP-43 is the primary or secondary pathological hallmark of neurodegenerative diseases, such as amyotrophic lateral sclerosis, half of frontotemporal dementia cases, and limbic age-related TDP-43 encephalopathy, which clinically resembles Alzheimer’s dementia. In such diseases, a biomarker that can detect TDP-43 proteinopathy in life would help to stratify patients according to their definite diagnosis of pathology, rather than in clinical subgroups of uncertain pathology. For therapies developed to target pathological proteins that cause the disease a biomarker to detect and track the underlying pathology would greatly enhance such undertakings. This article reviews the latest developments and outlooks of deriving TDP-43-specific biomarkers from the pathophysiological processes involved in the development of TDP-43 proteinopathy and studies using biosamples from clinical entities associated with TDP-43 pathology to investigate biomarker candidates.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TDP-43 ProteinopathiesAmyotrophic Lateral SclerosisFrontotemporal DementiaHumansBiomarkersDNA-Binding Proteins

Stichwörter der Autor:innen

TDP-43amyotrophic lateral sclerosisbiofluidbiomarkercerebrospinal fluiddementiafrontotemporal dementianeurodegeneration

Substanzen

BiomarkersDNA-Binding Proteins

Autor:innen und Institutionen

  • Department of Neurology, Klinikum Rechts der Isar, School of Medicine, Technical University of Munich, 81675 Munich, Germany.
  • Department of Quantitative Biomedicine, University of Zurich, 8057 Zurich, Switzerland.
  • Deutsches Zentrum für Neurodegenerative Erkrankungen, DZNE, 81377 Munich, Germany.
  • Munich Cluster for Systems Neurology (SyNergy), 81377 Munich, Germany.
  • Molecular Pathology, International Centre for Genetic Engineering and Biotechnology, 34149 Trieste, Italy.

ORCID-Profile: Paul Lingor, Magdalini Polymenidou, Emanuele Buratti

Zitieren

APA

Cordts, I., Wachinger, A., Scialo, C., Lingor, P., Polymenidou, M., Buratti, E., & Feneberg, E. (2023). TDP-43 Proteinopathy Specific Biomarker Development. Cells, 12(4), 597. https://doi.org/10.3390/cells12040597

Vancouver

Cordts I, Wachinger A, Scialo C, Lingor P, Polymenidou M, Buratti E, et al. TDP-43 Proteinopathy Specific Biomarker Development. Cells. 2023;12(4):597. doi:10.3390/cells12040597

BibTeX
@article{Cordts2023,
  author = {Cordts, Isabell and Wachinger, Annika and Scialo, Carlo and Lingor, Paul and Polymenidou, Magdalini and Buratti, Emanuele and Feneberg, Emily},
  title = {TDP-43 Proteinopathy Specific Biomarker Development},
  journal = {Cells},
  year = {2023},
  volume = {12},
  number = {4},
  pages = {597},
  doi = {10.3390/cells12040597}
}
Kostenlos starten →